Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

Comparing laparoscopic and open surgery for advanced stomach cancer

Official title: Prospective Randomized Controlled Multicenter Clinical Trial For Comparison Of Long-term Outcomes Between Laparoscopic And Open Total Gastrectomy In Patients With Locally Advanced Gastric Cancer

Run by Shanghai Zhongshan Hospital · NCT04710758 · Data updated 2026-11-12

This study is testing whether laparoscopic surgery is better than open surgery for people with advanced stomach cancer in terms of recovery and long-term health outcomes.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment1018 (estimated)
SponsorShanghai Zhongshan Hospital
Academic / other
Drugs / interventionschemotherapy, immunotherapy
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedJanuary 20, 2021
Main results expectedDecember 31, 2028
Study endsDecember 31, 2028
Registry record updatedSeptember 22, 2025
Trial IDNCT04710758 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18-75 with locally advanced gastric adenocarcinoma who are eligible for total gastrectomy.

Probably not a fit

Patients with a history of upper abdominal surgery or those who have received prior treatments like chemotherapy or radiotherapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The CLASS-07 trial is a multicenter, randomized controlled trial aimed at comparing the long-term outcomes of laparoscopic total gastrectomy (LTG) versus open total gastrectomy (OTG) in patients with locally advanced gastric cancer. This study will evaluate overall survival, disease-free survival rates, morbidity and mortality rates, recurrence patterns, and postoperative recovery over a three-year period. By focusing on patients with clinical stage T2-4aN0-3M0 gastric cancer, the trial seeks to provide robust evidence regarding the safety and efficacy of LTG compared to OTG.

Why it matters

Potential benefit: If successful, this study could provide evidence that laparoscopic surgery is a safer and more effective option for patients with advanced gastric cancer.

How similar studies have gone: Previous studies have shown that laparoscopic total gastrectomy can be safely performed for early-stage gastric cancer, but this trial is novel as it focuses on advanced cases.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Aged 18-75 years
2. Tumor located in the middle or upper third of the stomach, and curative resection is expected to be achievable by total gastrectomy with D2 lymphadenectomy (also apply to multiple primary cancers);
3. Primary lesion is pathologically diagnosed as gastric adenocarcinoma, such as papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, poorly cohesive carcinoma (including signet ring cell carcinoma and other variants), and mixed adenocarcinoma;
4. Clinical stage T2-4aN0-3M0 (According to AJCC-8th TNM staging system);
5. Expected survival \> 6 months
6. No invasion to Z-line;
7. BMI (Body Mass Index) \< 30 kg/m2
8. No history of upper abdominal surgery (except for laparoscopic cholecystectomy);
9. No prior treatment of chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc
10. Preoperative performance status (ECOG,Eastern Cooperative Oncology Group) of 0 or 1
11. Preoperative ASA (American Society of Anesthesiologists) scoring: I-III
12. Sufficient organ functions
13. Written informed consent

Exclusion Criteria:

1. Preoperative examinations indicate regional fusion of enlarged lymph nodes (max diameter ≥ 3.0cm) or enlargment of spleen hilus lymph nodes
2. Women during pregnancy or breast-feeding
3. Synchronous or metachronous (within 5 years) malignancies
4. Body temperature ≥ 38℃ before surgery or infectious disease with a systemic therapy indicated
5. Severe mental disease
6. Severe respiratory disease, FEV1 \< 50% of predicted
7. Severe hepatic and renal dysfunction
8. Unstable angina pectoris or history of myocardial infarction within 6 months
9. History of cerebral infarction or cerebral hemorrhage within 6 months
10. Continuous systemic steroid therapy within 1 month (except for topical use)
11. Gastric cancer complications (bleeding, perforation, obstruction) that requiring emergency surgery
12. Patients are participating or have participated in another clinical trial (within 6 months)

Where it's running

  • ZhongShan hospital FuDan university
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.